An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
With
Regeneron Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants with CRSwNP who completed the 52-weeks intervention period in a previous itepekimab CRSwNP Phase 3 clinical study (ie, EFC18418 or EFC18419) and for which an EOT visit occurred no later than 5 days before the enrollment visit of this study.
A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:
* Is not a women of childbearing potential (WOCBP), OR
* Is a WOCBP who agrees to follow the contraceptive guidance during the intervention period and for at least 20 weeks after the last dose of study intervention.
You may not be if
Participants are excluded from the study if any of the following criteria apply:
Diagnosis of a malignancy during parent study, except a squamous or basal cell carcinoma of the skin.
Any opportunistic infection during the parent study, such as tuberculosis (TB) or other infections whose nature or course may suggest an immunocompromised status.
Anaphylactic reactions or systemic allergic reactions that are related to IMP and require treatment during the parent study.
Any other situation that led to a permanent premature IMP discontinuation in parent trials.
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.